Literature DB >> 25444674

In vitro susceptibility of characterized β-lactamase-producing Gram-negative bacteria isolated in Japan to ceftazidime-, ceftaroline-, and aztreonam-avibactam combinations.

Ayumi Yoshizumi1, Yoshikazu Ishii2, Kotaro Aoki1, Raymond Testa3, Wright W Nichols3, Kazuhiro Tateda1.   

Abstract

Avibactam displays potent inhibition of extended-spectrum, AmpC, KPC and some OXA β-lactamases. We examined the combinations of avibactam with ceftazidime, ceftaroline and aztreonam by the broth microdilution method against Gram-negative bacteria harboring molecularly-characterized β-lactamase genes collected in Toho University, Japan. Bacterial isolates included: Ambler class A β-lactamase-producing Enterobacteriaceae (n = 26); class C β-lactamase-producing Enterobacteriaceae (n = 9) and class D β-lactamase-producing Acinetobacter baumannii (n = 9) and Enterobacteriaceae (n = 3). Ceftazidime-avibactam, ceftaroline-avibactam ands aztreonam-avibactam were active against the strains with an extended-spectrum β-lactamase (ESBL) or AmpC enzymes, but combination with avibactam did not reduce β-lactam MICs against A. baumannii with OXA β-lactamases including carbapenemases, such as OXA-40 and -69.
Copyright © 2014 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Antibiotic resistance; Avibactam; Aztreonam–avibactam; Ceftaroline–avibactam; Ceftazidime–avibactam

Mesh:

Substances:

Year:  2014        PMID: 25444674     DOI: 10.1016/j.jiac.2014.08.028

Source DB:  PubMed          Journal:  J Infect Chemother        ISSN: 1341-321X            Impact factor:   2.211


  8 in total

1.  Recent Advances in the Rational Design and Optimization of Antibacterial Agents.

Authors:  Jesse A Jones; Kristopher G Virga; Giuseppe Gumina; Kirk E Hevener
Journal:  Medchemcomm       Date:  2016-07-07       Impact factor: 3.597

Review 2.  Treatment of Infections Caused by Extended-Spectrum-Beta-Lactamase-, AmpC-, and Carbapenemase-Producing Enterobacteriaceae.

Authors:  Jesús Rodríguez-Baño; Belén Gutiérrez-Gutiérrez; Isabel Machuca; Alvaro Pascual
Journal:  Clin Microbiol Rev       Date:  2018-02-14       Impact factor: 26.132

Review 3.  The β-Lactams Strike Back: Ceftazidime-Avibactam.

Authors:  Evan J Zasowski; Jeffrey M Rybak; Michael J Rybak
Journal:  Pharmacotherapy       Date:  2015-08       Impact factor: 4.705

Review 4.  Pharmacological aspects and spectrum of action of ceftazidime-avibactam: a systematic review.

Authors:  Felipe Francisco Tuon; Jaime L Rocha; Marcelo R Formigoni-Pinto
Journal:  Infection       Date:  2017-11-07       Impact factor: 3.553

5.  Role of the Outer Membrane and Porins in Susceptibility of β-Lactamase-Producing Enterobacteriaceae to Ceftazidime-Avibactam.

Authors:  Jean-Marie Pagès; Sabine Peslier; Thomas A Keating; Jean-Philippe Lavigne; Wright W Nichols
Journal:  Antimicrob Agents Chemother       Date:  2015-12-14       Impact factor: 5.191

6.  Crystal Structure of OXA-58 with the Substrate-Binding Cleft in a Closed State: Insights into the Mobility and Stability of the OXA-58 Structure.

Authors:  Hiromichi Saino; Tomohiro Sugiyabu; Go Ueno; Masaki Yamamoto; Yoshikazu Ishii; Masashi Miyano
Journal:  PLoS One       Date:  2015-12-23       Impact factor: 3.240

Review 7.  Ceftolozane/tazobactam and ceftazidime/avibactam for the treatment of complicated intra-abdominal infections.

Authors:  Kellie J Goodlet; David P Nicolau; Michael D Nailor
Journal:  Ther Clin Risk Manag       Date:  2016-12-01       Impact factor: 2.423

8.  Interactions between Avibactam and Ceftazidime-Hydrolyzing Class D β-Lactamases.

Authors:  Jean-Marie Frère; Pierre Bogaerts; Te-Din Huang; Patrick Stefanic; Joël Moray; Fabrice Bouillenne; Alain Brans
Journal:  Biomolecules       Date:  2020-03-23
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.